Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial
Satoshi Suzuki, Akiomi Yoshihisa, Tetsuro Yokokawa, et al.
Journal of International Medical Research (2021) Vol. 49, Iss. 12
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
Nicola Riccardo Pugliese, Pierpaolo Pellicori, Francesco Filidei, et al.
Cardiovascular Research (2022) Vol. 118, Iss. 18, pp. 3536-3555
Open Access | Times Cited: 75
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
Kirsty McDowell, Paul Welsh, Kieran F. Docherty, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 1066-1076
Open Access | Times Cited: 47
Advances in pharmacotherapies for hyperuricemia
Federica Piani, Davide Agnoletti, Claudio Borghi
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 6, pp. 737-745
Closed Access | Times Cited: 26
Combination Treatment with Verinurad and Allopurinol in CKD
Hiddo J.L. Heerspink, Austin G. Stack, Robert Terkeltaub, et al.
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 5, pp. 594-606
Closed Access | Times Cited: 13
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis
Jianhao Deng, Peng‐hui Lai, Li‐shan Xie, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 3
Open Access | Times Cited: 7
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
Yoshiki Higa, Masahiro Hiasa, Hirofumi Tenshin, et al.
Antioxidants (2023) Vol. 12, Iss. 1, pp. 133-133
Open Access | Times Cited: 11
Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
Vipin Rawat, Patrick DeLear, Prarthana Prashanth, et al.
JCI Insight (2024) Vol. 9, Iss. 13
Open Access | Times Cited: 4
Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report
Toktam Faghihi, Farahnak Assadi
Clinical Therapeutics (2025)
Closed Access
Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Yuyang Ye, Guangzhi Liao, Ting Liu, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 9, pp. 379-379
Open Access | Times Cited: 7
Comparison of the therapeutic effects of febuxostat combined with a low‐purine diet and allopurinol combined with a low‐purine diet on the improvement of gout patients
Xuejiao Chen, Ye Tao, Yuna Dai, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 5
Closed Access | Times Cited: 2
The Cellular Genesis of Metabolic Syndrome and the Role of Anti-urate Drugs in Hyperuricemia Patients: A Systematic Review
Maujid Masood Malik, Nency Ganatra, Rosemary Siby, et al.
Cureus (2024)
Open Access | Times Cited: 2
Effect of febuxostat on the level of malondialdehyde‐modified low‐density lipoprotein, an oxidative stress marker: A subanalysis of the PRIZE study
Hiroki Teragawa, Atsushi Tanaka, Yuichi Fujii, et al.
Clinical Cardiology (2023) Vol. 46, Iss. 6, pp. 698-706
Open Access | Times Cited: 5
16S rRNA and Metagenomics Combined with UPLC-Q/TOF-MS Metabolomics Analysis Reveals the Potential Mechanism of Radix Astragali Against Hyperuricemia in Mice
Song Deng, Kaiwei Cai, Chaoying Pei, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1371-1386
Open Access | Times Cited: 5
Therapeutic effects of allopurinol on the function of left ventricular and activity of matrix metalloproteinase enzymes (MMPs) in patients with chronic heart failure
Hua Deng, Qiaolian Li, Dan Zhu
Cellular and Molecular Biology (2022) Vol. 68, Iss. 5, pp. 96-102
Open Access | Times Cited: 9
Development of Validated Stability Indicating HPTLC Method for Estimation of Febuxostat in Bulk and Tablet Dosage Form by Using QBD Approach
Vrushali Kharate, Mohini Kuchekar, Minal T. Harde, et al.
International Journal of Drug Delivery Technology (2022) Vol. 13, Iss. 02, pp. 542-550
Open Access | Times Cited: 8
Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches
Koyeli Girigoswami, Radhakrishnan Arunkumar, Agnishwar Girigoswami
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 1
Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases
Emiliano Fiori, Ludovica De Fazio, Chiara Pidone, et al.
Journal of Hypertension (2024) Vol. 42, Iss. 10, pp. 1665-1680
Closed Access | Times Cited: 1
Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice
Qian Wang, Dewei Peng, Bingyu Huang, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 361-361
Open Access | Times Cited: 3
Association between use of febuxostat and muscle injury: A disproportionality analysis and meta‐analysis of randomized controlled trials
Satoru Mitsuboshi, Kazumasa Kotake
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 3, pp. 956-966
Closed Access | Times Cited: 5
Association of Hyperuricemia with Impaired Left Ventricular Systolic Function in Patients with Atrial Fibrillation and Preserved Kidney Function: Analysis of the POL-AF Registry Cohort
Marcin Wełnicki, Iwona Gorczyca−Michta, Arkadiusz Lubas, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 12, pp. 7288-7288
Open Access | Times Cited: 4
Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
Vipin Rawat, Patrick DeLear, Prarthana Prashanth, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
Christiyanti Dewi, Falerina Puspita, Irma Melyani Puspitasari, et al.
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 731-743
Open Access | Times Cited: 2
Realities of modern urate-reducing therapy for gout
И. Г. Красивина, Л. Н. Долгова, N. V. Dolgov, et al.
Meditsinskiy sovet = Medical Council (2023), Iss. 10, pp. 116-126
Open Access | Times Cited: 1
Relationship between serum uric acid levels and uric acid lowering therapy with the prognosis of patients with heart failure with preserved ejection fraction: a meta-analysis
Linzhi Li, Ying Chang, Fei Li, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access
Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis
Yilong Yan, Ying Bai, Jiawei Wang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-9
Closed Access
Page 1 - Next Page

Scroll to top